Radioactive therapy targets Hard-to-Treat kidney cancer
NCT ID NCT06959433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a radioactive drug called Lu-177 PSMA in 20 people with metastatic clear cell kidney cancer that has worsened after at least two prior treatments. The drug is designed to seek out and destroy cancer cells while limiting damage to healthy tissue. Researchers will monitor side effects and measure tumor response using standard criteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lu-177 PSMA-617 (a radioactive drug that targets cancer cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced kidney cancer who have run out of standard therapies.
- What could go wrong
- This is a very small early-phase trial (only 20 people), so results may not apply to everyone. The treatment involves radiation, which can cause side effects like damage to kidneys, liver, or salivary glands.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test aims to spot hidden cancer cells in 9 tumor types
- New imaging-guided radiation aims to halt kidney cancer spread
- New cocktail of three drugs shows promise for tough kidney cancers
- Radiation boost may extend life in advanced kidney cancer
- Radiation may reboot Cancer-Fighting immune drugs in spreading tumors
- New study aims to crack the code of kidney cancer treatment response